Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Receives 2025 Charles A. Sanders, MD, Partnership Award From the Foundation for the National Institutes of Health

Core Insights - Alexandria Real Estate Equities, Inc. has been awarded the 2025 Charles A. Sanders, MD, Partnership Award by the Foundation for the National Institutes of Health (FNIH) for its leadership in a public-private partnership aimed at advancing precision medicine for depression [1][2] - The initiative, known as Multi-Level Assessment & Phenotyping in Depression (MAP-D), seeks to develop a comprehensive framework for treating major depressive disorder, which affects over 21 million adults in the U.S. annually [2][3] - The MAP-D program aims to create a large depression research dataset, validate new measurement methods, and identify biomarkers to guide treatment decisions [3][4] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science real estate investment trust (REIT) with a market capitalization of $25.7 billion as of June 30, 2025, and operates in key life science innovation clusters across North America [5][6] - The company specializes in developing collaborative Megacampus ecosystems and has a significant asset base, including 39.7 million rentable square feet (RSF) of operating properties and 4.4 million RSF of properties under construction [5][6] - Alexandria also provides strategic capital to transformative life science companies through its venture capital platform, enhancing its role in the life science ecosystem [6]